Global Giant Cell Arteritis Therapeutic Market Growth (Status and Outlook) 2023-2029

Global Giant Cell Arteritis Therapeutic Market Growth (Status and Outlook) 2023-2029

The global Giant Cell Arteritis Therapeutic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Giant Cell Arteritis Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Giant Cell Arteritis Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Giant Cell Arteritis Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Giant Cell Arteritis Therapeutic players cover Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Novartis AG, AbbVie, Inc., Bristol-Myers Squibb Company and Abbott, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.

LPI (LP Information)' newest research report, the “Giant Cell Arteritis Therapeutic Industry Forecast” looks at past sales and reviews total world Giant Cell Arteritis Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Giant Cell Arteritis Therapeutic sales for 2023 through 2029. With Giant Cell Arteritis Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Giant Cell Arteritis Therapeutic industry.

This Insight Report provides a comprehensive analysis of the global Giant Cell Arteritis Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Giant Cell Arteritis Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Giant Cell Arteritis Therapeutic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Giant Cell Arteritis Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Giant Cell Arteritis Therapeutic.

This report presents a comprehensive overview, market shares, and growth opportunities of Giant Cell Arteritis Therapeutic market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Prednisone
Methotrexate
Tocilizumab
Aspirin

Segmentation by application
Corticosteroids
Immunosuppressive Agents
Anticoagulants
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Sanofi
Kiniksa Pharmaceuticals, Ltd.
Regeneron
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd.
Novartis AG
AbbVie, Inc.
Bristol-Myers Squibb Company
Abbott
Johnson & Johnson Services, Inc.
Johns Hopkins Hospital
Fortis Healthcare
American College of Rheumatology
Duke University Health System
Lahey Clinic Foundation

Please note: The report will take approximately 2 business days to prepare and deliver.